Background Although the association between cytosine-adenine-guanine (CAG) repeat length and age at onset of Huntington's disease is well known, improved prediction of onset would be advantageous for clinical trial design and prognostic counselling. We compared various measures for tracking progression and predicting conversion to manifest Huntington's disease.
Introduction
Huntington's disease is an autosomal dominant neurodegenerative disease caused by expansion of the trinucleotide cytosine-adenine-guanine (CAG) in the fi rst exon of the Huntingtin (HTT) gene. There is a well known association between the length of the CAG mutation and age at disease onset, 1 although substantial individual variation is evident. Over the past decade, results from the Neurobiological Predictors of Huntington's Disease study (PREDICT-HD; ClinicalTrials.gov number NCT00051324) and others [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] have documented disease-related changes of clinical features and biomarkers in people with the CAG expansion but not yet diagnosed with Huntington's disease. 12, 13 If they are to be useful, clinical and biological markers should be predictive of landmark events, such as clinical motor diagnosis.
Improved predictability of Huntington's disease diagnosis could advance design of future studies, experimental trials, and clinical care through improved prognosis and earlier intervention. In this study, we compared genetic, demographic, motor, cognitive, psychiatric, functional, and imaging measures for the prediction of conversion to manifest Huntington's disease in people with CAG expansion.
Methods

Study design and participants
In this prospective observational study, we assessed the ability of various measures to predict time to motor diagnosis (fi rst occurrence) in additon to CAG repeat length, age, and the interaction of CAG repeat length and age. Eligible participants were from 33 centres (in six countries [USA, Canada, Germany, Australia, Spain, and UK]) recruited to the PREDICT-HD study, had more than 35 HTT CAG repeats, had previous and independent genetic testing for Huntington's disease, and had less than the highest rating (ie, <4) on the diagnostic confi dence level (DCL) of the Unifi ed Huntington's Disease Rating Scale (UHDRS) at the beginning of the study. Exclusion criteria included presence of other CNS disease, injury, or developmental disorder, or evidence of an unstable medical or psychiatric illness. Full details of the exclusion criteria have been published previously. 14 Control participants without a CAG expansion were included in an ancillary analysis to establish the variability and range of total motor score in participants without the gene mutation for Huntington's disease. All participants had to have independently undergone predictive testing for the Huntington's disease gene mutation, and those who had fewer than 36 repeats were classifi ed as controls.
All participants provided written informed consent and were treated in accordance with the Declaration of Helsinki. The study was approved by institutional review boards at all participating institutions.
Procedures
Data for the longitudinal measures of interest were collected between September, 2002, and July, 2014. Findings were reviewed by the study executive committee (members listed in the appendix), who made decisions about use of the data in the study; if a control participant was seen to have a previously undetected neurological diagnosis, the participant and all of his or her data were excluded. All abnormalities in clinical and imaging data were forwarded to clinical investigators at the relevant study site for additional review and discussion. When the data were suggestive of abnormalities in function or brain imaging outside of the ranges reported in Huntington's disease, follow-up clinical investigations were encouraged.
We selected 40 longitudinal measures on the basis of their sensitivity to the detection and progression of Huntington's disease (appendix). 12 Motor measures were total motor score from the UHDRS and the chorea, bradykinesia, oculomotor, dystonia, and rigidity subdomains from the 15-item standardised UHDRS motor assessment. Cognitive measures were the Stroop colour and word test (three measures: word, colour, and interference), the Symbol Digit Modalities Test, the University of Pennsylvania Smell Identifi cation Test, emotion recognition, speeded tapping, time production (also known as paced tapping), and the Trail Making Test (parts A and B). Psychiatric measures were the Global Distress Index and four subscales of the Symptom Checklist 90, the Beck Depression Inventory, and three subscales of the Frontal Systems Behavioral Scale. Imaging measures were intracranial-corrected volumes for putamen, accumbens, caudate, hippocampus, thalamus, globus pallidus, CSF, and lobar white and grey matter. Functional outcome measures were the total functional capacity and functional activity scale from the UHDRS, participant and companion ratings from the WHO Disability Assessment Schedule (version 2.0), and the Everyday Cognition rating scale (participant and companion ratings). Motor diagnosis of Huntington's disease was defi ned as a rating of 4 on the DCL of the UHDRS (ie, meets the operational defi nition of the unequivocal presence of an otherwise unexplained extrapyramidal movement disorder in a person at risk for Huntington's disease, with ≥99% confi dence). The DCL was administered by a movement disorder specialist after the 15-item standardised motor assessment.
Statistical analysis
We simultaneously modelled time to motor diagnosis and longitudinal change in the aforementioned variables using joint modelling for survival and longitudinal data (appendix). 15, 16 The intention was to model progression to Huntington's disease diagnosis over the entire lifespan by use of the time metric of age adjusted for CAG expansion.
The survival model was a Cox regression model and the longitudinal model was a linear mixed-eff ects regression model. The time metric for both was age adjusted for genetic burden (CAG expansion), known as the CAG-Age Product (CAP; [age in years at baseline] × [CAG-33·66]). 17 CAP refl ects the cumulative exposure to the eff ects of mutant huntingtin and is similar to other CAG-based and age-based measures. [18] [19] [20] We used CAP at motor diagnosis or censoring for the observation time in the Cox model, and CAP was the longitudinal time metric for the linear mixed-eff ects regression model. CAP as specifi ed in this analysis is time-varying and represents age adjusted for CAG expansion. Because of the variability in age at study entry, the annual measurements span almost the entire adult age range, which allows inferences about motor diagnosis risk through life. The natural CAP intercept (baseline) is 0, denoting birth. Predictive power is meaningless at birth because the clinical measures have not been assessed. We chose the baseline CAP cross-section of 290 as the intercept because this is the value at which motor signs begin to appear in the PREDICT-HD cohort. 6 At this baseline, the putative predictive measures might have suffi cient variability for an association with later motor diagnosis to be identifi ed. A CAP value of 290 corresponds to the rounded ages of 40, 35, and 28 years for individuals with 41 CAG repeats (25th percentile), 42 repeats (median), and 44 repeats (75th percentile), respectively. Percentile values are from the PREDICT-HD population in this study.
Each outcome was standardised and cubic splines based on fi ve knots (1st, 25th, 50th, 75th, and 99th percentiles) were used in the linear mixed-eff ects [12] [13] [14] 21 We fi tted two joint models for each measure: a reduced model that provided information about the baseline prediction by a marker of the hazard for motor diagnosis (at a CAP of 290), and a full model that incorporated change of the marker in the prediction. A signifi cant g estimate meant that a measure accounted for variability in the timing of diagnosis in addition to CAG expansion and age. The covariates in all models were sex and number of years in education. For cognitive measures, depression (Beck Depression Inventory) was added as a covariate to account for mood changes. For imaging measures, fi eld strength was added as a covariate because some sites updated their scanners during the study. The hazard ratio (HR) was computed as exp(g) and served as the primary eff ect size (HR -1 was used when the g estimate was negative). A signifi cant HR indicates that a measure adds to prediction beyond that of CAG and age (as indexed by CAP).
In a subsequent preplanned analysis, we characterised the risk of motor diagnosis over the lifespan of individuals with the gene mutation for Huntington's disease. We used individual fi tted values from the linear mixedeff ects regression spline model to obtain baseline values at a CAP of 290. We used the baseline information in a separate (ie, not joint) Cox model to predict time to diagnosis along with the covariates. We estimated the cumulative hazard on the basis of the fi tted models for various baseline predictor values.
We also did a preplanned ancillary analysis to examine the natural history of key variables from the premanifest phase to diagnosis; all people who were diagnosed with Huntington's disease during the study with a DCL of 4 were used for this analysis. 206 control participants were used in a post-hoc analysis along with all 1078 geneexpanded participants examining the heterogeneity of the UHDRS total motor score (appendix). The time metric was years to diagnosis and we used cubic spline curves with linear mixed-eff ects regression models to allow for non-linear trends over time.
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
1078 individuals with a CAG expansion from the PREDICT-HD study whose data had been entered into the database by April, 2014, were included in this analysis (table 1, appendix). The study concluded in August, 2014. Participants were followed up for a mean of 5·1 years (SD 3·3; range 0·0-12·0). 959 (89%) participants had data for two or more years, and 118 (11%) had data for only one timepoint (appendix). 225 (21%) participants received a motor diagnosis during the study, as defi ned by the DCL. 260 control participants (with fewer than 36 CAG repeats) were included in an ancillary analysis to examine lower-bound cutoff s of total motor score based on normal ageing (appendix). Figure 1 shows age at diagnosis as a function of CAG expansion for the converters who obtained a motor diagnosis during the study. The squared correlation (r²) between CAG repeat length and age at Huntington's disease diagnosis was 0·53. Age at diagnosis can vary widely for individuals with the same CAG expansioneg, for patients with 40 CAG repeats, the range for age at diagnosis ranges from 37·6 to 68·8 years, and the diff erence between the fi rst and third quartile is 15 years. Mean CAP at motor diagnosis was 447, which for the sample CAG quartiles of 41 repeats, 42 repeats, and 
Combined (n=1078)
Women 540 (63%) 147 (65%) 687 (64%)
Time in study (years) 4·28 ( 
Motor domain
Total motor score 1073 3661 225
Lobar grey matter 967
Globus pallidus 980 1774 147
Lobar white matter 952 Table 2 shows the joint modelling results (each measure was tested separately). The longitudinal variables are sorted within each domain on the basis of the absolute Z value of g from the full model. The column for reducedmodel g estimates shows that the baseline information was a signifi cant predictor of the hazard of motor diagnosis for 37 of 40 measures. A comparison shows that the full-model g estimates were larger than the reduced model estimates in absolute value for every measure for which a full-model estimate could be made. Thus, prediction of motor diagnosis based on baseline information and longitudinal change information was stronger than prediction based only on baseline information.
Based on the results for the full model, the largest eff ect size in the motor domain was for total motor score (table 2). For the imaging domain, putamen volume was the strongest predictor, and the strongest cognitivedomain predictor was the Stroop word score. The best psychiatric-domain predictor was executive functioning, and total functional capacity was the strongest functional measure (table 2) . Figure 2 shows the cumulative hazard (accumulated risk rate) as a function of CAP for putamen volume, total motor score, and Stroop word test. These measures were the strongest predictors within the three strongest domains (functional and psychiatric measures, although signifi cant, had weaker prediction in terms of the estimated HRs; table 2). The no-predictor model represents the cumulative hazard associated with only CAG expansion and age (both variables are indexed by CAP). The baseline was set to a CAP of 290, and the predictor curves were generated for values of the variables representing no deterioration and advanced deterioration. The no-deterioration values (total motor score 0, ratio of putamen volume to intracranial volume 0·008, and Stroop word score 183) were the most extreme values in the sample (minimum for total motor score, and maximum for the others). The advanceddeterioration values (total motor score 15, ratio of putamen volume to intracranial volume 0·0038, Stroop word score 85) were the medians for participants in the sample with a DCL of 3. When there is advanced deterioration at baseline, the cumulative hazard for the predictors increases at a faster rate than when the covariates are ignored or there is no deterioration. Conversely, when there is no deterioration at baseline, the cumulative hazard for the predictors increases at a slower rate than when the covariates are ignored. Figure 3 shows individual empirical curves and fi tted spline curves for the participants who received a motor diagnosis during the study, for the two strongest predictors in each domain (based on absolute Z values). Descriptive information about all the variables for these participants at study entry and time of diagnosis is provided in the appendix.
Discussion
Our results show that several clinical and biological measures can improve the prediction of Huntington's disease diagnosis beyond that obtained by CAG repeat length and age alone. The strongest predictors (in terms of absolute Z values) were in the motor (total motor score), imaging (putamen volume), and cognitive (Stroop word test) domains. Psychiatric and functional measures were signifi cant, but relatively weak, predictors of manifest Huntington's disease. These fi ndings suggest that models for the prediction of Huntington's disease onset can be substantially improved by use of straightforward clinical (motor and cognitive) assessments (panel). Volumetric MRI measures can also be used as predictors.
Because CAP is age adjusted for CAG repeat number, the cumulative risk of diagnosis increases as CAP increases because the likelihood of motor diagnosis increases as people age. As a result, the no-predictor curve in fi gure 2 represents the accumulated risk rate that could be predicted on the basis of only CAG and age (and their interaction). When a predictor is taken into account, the risk profi le is modifi ed on the basis of the predictor value at baseline. The modifi cation can result in a very diff erent risk profi le compared with CAP alone. For people with advanced deterioration at baseline, the risk of motor diagnosis is estimated to be greater when a predictor is used, whereas for people with no or little deterioration, the risk is less than that predicted by CAG and age alone. Thus, a clinical predictor is informative for risk assessment for future motor diagnosis beyond the information provided by CAG and age. Further research is needed to detect additional genetic, environmental, and biological predictors of motor diagnosis, since predictors of disease onset might also lead to new avenues for intervention. In a follow-up analysis, we assessed a composite of total motor score, putamen volume, and Stroop word test, but use of the composite did not improve prediction compared with the individual measures (data not shown). A complication of our cumulative hazard results is that the maximum Stroop word scores might not represent the absence of deterioration, but rather an advanced education level or high intelligence. The converse also holds for low Stroop word scores. However, the association identifi ed remains valid: superior or inferior Stroop word test performance at baseline aff ects the future estimate of risk. Similar considerations are also relevant for putamen volume and total motor score.
The best motor predictor of Huntington's disease diagnosis was total motor score, which is unsurprising since diagnosis is based on motor fi ndings. This fi nding emphasises the value of the motor examination, even in the premanifest period. It is consistent with previous fi ndings of subtle motor abnormalities years before diagnosis, which can accelerate just before diagnosis. 6, 22 Subdomains for chorea, bradykinesia, and oculomotor abnormalities were also predictive.
The strongest predictive cognitive measure was the Stroop word test, a timed reading task. Previously, we documented 19 cognitive tasks that showed signifi cant longitudinal change before motor diagnosis. 12 Our results suggest that performance on just one of the most robust of these tests can signifi cantly improve diagnostic prediction. The most robust cognitive tests take just a few minutes to do and can be used in various settings, making them valuable for design of future studies and clinical practice.
The usefulness of brain imaging markers in the detection of Huntington's disease has been documented in several studies over the past decade. 2, 23, 24 Striatal volume consistently distinguishes people with the HTT disease mutation from those without and tracks disease progression. 12 Our results show that imaging measures were among the best predictors of diagnosis in premanifest Huntington's disease, and their preeminence in this study off ers biological validity for the models presented (ie, Stroop and total motor score have biological validity since they are associated with volume loss on MRI, which is a characteristic of Huntington's disease). The use of imaging measures might translate into advances in clinical trial design, with respect to both selection criteria and outcome measures. Imaging might also be useful in clinical care and education, although broad dissemination of imaging predictors would necessitate standardisation of image acquisition and analysis protocols for clinical care.
Our fi ndings validate and extend results from other studies that used smaller samples, shorter follow-up, and varying endpoints. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Overall, strong evidence now exists that cognitive, motor, and imaging defi cits are evident before traditional motor diagnosis and might provide an opportunity for earlier intervention, treatment, and support. The predictive usefulness of the markers suggested by our results can be integrated into clinical trial design and be used to advance clinical care through refi ned diagnostic and prognostic guidelines.
Much evidence exists that the diagnosis of Huntington's disease is made fairly late in the disease course, after a high proportion of people already show substantial cognitive decline, 13, 25 psychiatric abnormalities, [26] [27] [28] and motor impairment, 6, 22 and at a time when, on average, more than half of their striatal volume is lost. 2 Notably, many people are diagnosed after major changes in functioning have occurred (eg, loss of usual employment or ability to drive) and after a reduction in basic activities of daily living (requiring fi nancial or care assistance). [29] [30] [31] [32] An earlier diagnosis might be benefi cial with respect to potential future therapeutic interventions and life planning. 33, 34 Our data suggest some interesting models for the course of Huntington's disease. Based on what is to our knowledge the largest sample of prospectively followed people who converted to Huntington's disease, our results suggest that many of the clinical markers of
Panel: Research in context
Systematic review
We searched PubMed and Medline for articles published in English up to Aug 25, 2014, using the search terms "Huntington disease", "longitudinal", "prospective", "onset", and "diagnosis". We restricted our search to reports of studies of human participants aged 19 years or older. We also reviewed the reference lists of identifi ed articles. Since no previous publications from the PREDICT-HD study had examined comprehensive prediction of diagnosis, all such reports were excluded. We identifi ed seven reports 3,5,7-11 of studies in which prospective data were used to predict Huntington's disease diagnosis on the basis of motor criteria. Sample sizes for participants prospectively diagnosed were 21-70 and length of follow-up varied from 2·5 to 5 years. Four 3, [8] [9] [10] of the seven studies identifi ed investigated only cognitive predictors, one study 7 investigated only dietary predictors, and the remaining two studies 5, 11 examined various comprehensive predictors of prospective diagnosis. Studies showed that cognitive tests of executive control, subtle motor abnormalities, brain imaging, and subjective complaints were predictive of Huntington's disease diagnosis. Using data from the Huntington Study Group, Langbehn and Paulsen 5 showed cognitive measures, motor measures, and self-reported symptoms to be predictive of traditional motor diagnosis (ie, a rating of 4 on the Unifi ed Huntington's Disease Rating Scale). Although Tabrizi and colleagues 11 did not examine traditional motor criteria for diagnosis, their fi ndings suggest that cognitive measures, quantitative motor measures, and imaging measures are predictive of motor onset.
Interpretation
Our study is the fi rst to use comprehensive longitudinal assessments to prospectively predict traditional motor diagnosis in Huntington's disease. Joint modelling of longitudinal change and time to Huntington's disease diagnosis identifi ed several signifi cant phenotypic and biological predictors (eg, imaging) that might be useful as endpoints in clinical trials and for participant selection. These fi ndings fi ll a gap in the scientifi c literature by identifying predictors of Huntington's disease diagnosis in addition to CAG expansion and age. Our results provide insights into the nature of Huntington's disease progression and show that brief clinical assessments have the potential to enhance prediction of motor diagnosis.
disease progression (ie, cognitive, sensory, and psychiatric variables) progress in a near linear fashion and decline in concert with biological markers of brain imaging abnormalities. Additionally, they suggest that motor and functional variables progress in a non-linear way, which is refl ected by the fact that motor signs and functional impairment become evident only at specifi c points of disease progression. Several possible explanations could account for the variations in disease progression. One explanation might be that atrophy of each individual brain region proceeds fairly linearly, beginning with the striatum, but as additional brain regions undergo degeneration and dysfunction, their combined eff ect causes acceleration of the clinical expression of disease. An alternative hypothesis is that, at some point, a threshold of brain volume is surpassed, triggering acceleration of motor and functional defi cits. Researchers making the crucial choice of outcome measures for clinical trials might benefi t from our fi ndings, such that studies can be better designed to improve the possibility of documenting therapeutic eff ects, should they occur. In view of the variation in motor and functional changes across the disease course, selection of participants at varying disease stages could drastically change interpretations made about the eff ects of an intervention.
Some qualifi cations should be taken into account in the interpretation of these research fi ndings. The baseline for prediction was defi ned at a disease burden score at which it is known that the PREDICT-HD sample has the earliest detectable change in motor signs. 6 Should other samples suggest the examination of other CAP scores as baseline in the premanifest period, the estimates could vary accordingly. Encouragingly, however, our fi ndings are similar to those reported from studies of smaller samples followed up for shorter durations. 11 Replication in other samples will continue to refi ne the predictive models used. Translation of these models into clinical care will require further research to determine how such information can be integrated into genetic counselling. Advances in diagnosis and prognosis will depend on clinical consensus and guidelines. Implementation of new diagnostic and prognostic criteria will necessitate patient-centred clinical outcome research to document best practices for families aff ected by Huntington's disease who choose to obtain greater prognostic information than they do at present.
Additional caveats concern the variability noted in this study. Individual values for the predictive measures assessed varied widely, especially for total motor score. Individuals might have had diff erent motor examiners over time, which could infl ate the variability of the total motor score. Early in the study, substantial variation in total motor score was noted and eff orts were made to assure data integrity (appendix). Another source of heterogeneity was introduced by the upgrading of MRI scanners at all sites (from 1·5T to 3T). However, we adjusted for scanner strength, both in the image processing and in the statistical analysis (appendix). Despite the substantial variability, both the total motor score and the imaging measures were among the strongest predictors. Thus, potential sources of variance such as diff erent raters and scanners did not outweigh the predictive power of the measures. Future studies that constrain sources of variance by having the same scanners or the same people assessing motor function might show even larger eff ect sizes than those reported here.
The detection and tracking of early clinical signs and symptoms in Huntington's disease is crucial to choosing outcome measures useful for clinical trials. Treatments that aff ect symptoms of disability in motor, cognitive, psychiatric, and functional domains can be essential components of clinical trials and are often mandated by regulatory agencies. The outcome measures reported here might have value in the selection of research participants and might help researchers to choose outcomes that are associated with a meaningful endpoint-that of being diagnosed.
